NVCT vs TENX: fair value comparison
Nuvectis Pharma, Inc. and Tenax Therapeutics, Inc. · Updated 2026-10-19
NVCT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. TENX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TENX currently ranks higher by quality score.
| NVCT | TENX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $18.60 | $1.36 |
| 12-month range | $5.65–$28.53 | $1.36–$18.32 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #301 of 301 Healthcare | #298 of 301 Healthcare |
| Quality grade | F | F |
| Margin trend | — | Contracting |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: NVCT fair value analysis · TENX fair value analysis